Xiaojuan Li

694 citations
8 papers · 415 indexed · h-index 6
Topics
Cancer-related molecular mechanisms research (5 papers)RNA modifications and cancer (3 papers)Circular RNAs in diseases (2 papers)
Partner nations
ChinaUnited States

In The Last Decade

Xiaojuan Li

8 papers receiving 411 citations

Peers

Xiaojuan Li
Comparison fields: 5 of 63
  • Cancer Research 181
  • Molecular Biology 170
  • Rheumatology 96
  • Surgery 87
  • Biomedical Engineering 65
Replace Zhigang You with:
Zhigang You United States
Peter Sang Uk Park United States
Hao Ding China
F. Andreu Spain
Amabelle B. Cruz United States
Peiguo Wang China
Wenqiang Luo China
Lei Tang China
Francesca Valcamonico Italy
Yunchao Huang China
Xiaojuan Li relative to Zhigang You United States Zhigang You's profile →
Citations per field
00.5×4.1×
Zhigang You · 1×
Citations per year

Countries citing papers authored by Xiaojuan Li

Since Specialization
Citations

This map shows the geographic impact of Xiaojuan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojuan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojuan Li more than expected).

Fields of papers citing papers by Xiaojuan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojuan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojuan Li. The network helps show where Xiaojuan Li may publish in the future.

Co-authorship network of co-authors of Xiaojuan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojuan Li. A scholar is included among the top collaborators of Xiaojuan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojuan Li. Xiaojuan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
#WorkIndexed citations
1 1
2 7
3
KIF3A inhibits nasopharyngeal carcinoma proliferation, migration and invasion by interacting with β-catenin to suppress its nuclear accumulation.
2
4 5
5 87
6 39
7 111
8 163

About Xiaojuan Li

Xiaojuan Li is a scholar working on Cancer Research, Immunology and Allergy and Molecular Biology, having authored 8 papers that have together received 415 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (5 papers), RNA modifications and cancer (3 papers) and Circular RNAs in diseases (2 papers). The work is most often cited by research in Cancer Research (181 citations), Rheumatology (96 citations) and Orthopedics and Sports Medicine (28 citations). Xiaojuan Li has collaborated with scholars based in China and United States. Frequent co-authors include Reed F. Busse, Eric Han, Sharmila Majumdar, Xin Qu, Zewei He, Zuozhang Yang, Yihao Yang, Ya Zhang, Geng Dong and Tiewei Li. Their work appears in journals such as Magnetic Resonance in Medicine, Life Sciences and Food and Chemical Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026